Vol 7, No 2 (2021)
Review paper
Published online: 2021-07-21
Get Citation

Historia diagnostyki i leczenia tocznia rumieniowatego układowego

Wiktor Schmidt12, Katarzyna Pawlak-Buś12, Piotr Leszczyński12
DOI: 10.5603/FR.2021.0012
·
Forum Reumatologiczne 2021;7(2):71-77.
Affiliations
  1. Katedra i Klinika Reumatologii, Rehabilitacji i Chorób Wewnętrznych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Fredry 10, 61-701 Poznań
  2. Oddział Reumatologii i Osteoporozy, Szpital im. Józefa Strusia w Poznaniu, ul. Szwajcarska 3, 61-285 Poznań, Poland

paid access

Vol 7, No 2 (2021)
Prace poglądowe
Published online: 2021-07-21

Abstract

Toczeń rumieniowaty układowy (SLE, systemic lupus erythematosus) ze względu na liczne manifestacje kliniczne i laboratoryjne jest jedną z najbardziej złożonych jednostek chorobowych, z którymi mają do czynienia reumatolodzy w swojej praktyce klinicznej. Równie skomplikowana co sama choroba jest jej historia, której początki sięgają średniowiecza, ale właściwy opis choroby i identyfikacja poszczególnych manifestacji miała miejsce dopiero w drugiej połowie XX wieku. Historia SLE jest rozdziałem nadal otwartym — w ostatnich latach opracowano nowe kryteria klasyfikacyjne choroby, a także nowe,
skuteczne metody leczenia. Celem pracy było przybliżenie rysu historycznego tocznia rumieniowatego układowego z uwzględnieniem postępów w zakresie jego definicji, diagnostyki i leczenia.

Abstract

Toczeń rumieniowaty układowy (SLE, systemic lupus erythematosus) ze względu na liczne manifestacje kliniczne i laboratoryjne jest jedną z najbardziej złożonych jednostek chorobowych, z którymi mają do czynienia reumatolodzy w swojej praktyce klinicznej. Równie skomplikowana co sama choroba jest jej historia, której początki sięgają średniowiecza, ale właściwy opis choroby i identyfikacja poszczególnych manifestacji miała miejsce dopiero w drugiej połowie XX wieku. Historia SLE jest rozdziałem nadal otwartym — w ostatnich latach opracowano nowe kryteria klasyfikacyjne choroby, a także nowe,
skuteczne metody leczenia. Celem pracy było przybliżenie rysu historycznego tocznia rumieniowatego układowego z uwzględnieniem postępów w zakresie jego definicji, diagnostyki i leczenia.

Get Citation

Keywords

toczeń rumieniowaty układowy; przeciwciała przeciwjądrowe; toczniowe zapalenie nerek

About this article
Title

Historia diagnostyki i leczenia tocznia rumieniowatego układowego

Journal

Forum Reumatologiczne

Issue

Vol 7, No 2 (2021)

Article type

Review paper

Pages

71-77

Published online

2021-07-21

DOI

10.5603/FR.2021.0012

Bibliographic record

Forum Reumatologiczne 2021;7(2):71-77.

Keywords

toczeń rumieniowaty układowy
przeciwciała przeciwjądrowe
toczniowe zapalenie nerek

Authors

Wiktor Schmidt
Katarzyna Pawlak-Buś
Piotr Leszczyński

References (68)
  1. Felten R, Lipsker D, Sibilia J, et al. The history of lupus throughout the ages. J Am Acad Dermatol. 2020 [Epub ahead of print].
  2. Smith CD, Cyr M. The history of lupus erythematosus. From Hippocrates to Osler. Rheum Dis Clin North Am. 1988; 14(1): 1–14.
  3. Bateman TA. Practical Synopsis of Cutaneous Diseases According to the Arrangement of Dr. Willan: Exhibiting a Concise View of the Diagnostic Symptoms and the Method of Treatment. Crissy. 1824.
  4. Cazenave P-LA, Schedel HÉ. Manual of Diseases of the Skin. Langley. 1846.
  5. von He, Canstatt B, Eisenmann G. Jahresbericht über die fortschritte der gesammten medicin in allen ländern. F Enke. 1845.
  6. Kohn M. Zum Wesen und zur Therapie des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1869; 1(1): 18–41.
  7. Neue Beiträge zurKenntniss des Lupus erythematosus. Archiv für Dermatologie und Syphilis. 1872; 4(1): 36–78.
  8. Osler W. On the visceral complications of erythema exudativum multiforme. Am J Med Sci. 1895; 110: 629–646.
  9. Hutchinson J, Hutchinson J, Hutchinson J. Harveian Lectures on Lupus. Br Med J. 1888; 1(1410): 6–10.
  10. Sequeira JH, Balean H. Lupus Erythematosus: A Clinical Study of Seventy-One Cases. Br J Dermatol. 1902; 14(10): 367–379.
  11. Keith N, Rowntree LA. study of renal complications of disseminated lupus erythematosus: report of four cases. Trans Assoc Am Physicians. 1922; 37: 487–502.
  12. Baehr G, Klemperer P, Schifrin AA. diffuse disease of the peripheral circulation (usually associated with lupus erythematosus and endocarditis). Trans Assoc Am Physicians. 1935; 50: 139–155.
  13. Harvey AM, Shulman LE, Tumulty PA. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore). 1954; 33(4): 291–437.
  14. Haserick JR, Long R. Systemic lupus erythematosus preceded by false-positive serologic tests for syphilis: presentation of five cases. Ann Intern Med. 1952; 37(3): 559–565.
  15. Churg J, Sobin LH. Renal Disease: Classification and Atlas of Glomerular Diseases. Igaku-Shoin. 1982.
  16. Macleod J, Aberd MD, Lond M. A lecture on systemic lupus erythematosus: its nature and treatment. . The Lancet. 1908; 172(4444): 1271–1275.
  17. Pulay E. Stoffwechselpathologie und hautkrankheiten. Dermatol Wochenschr. 1921; 73: 1217–1234.
  18. Libman E, Sacks B. hitherto undescribed form of valvular and mural endocarditis. Archives of Internal Medicine. 1924; 33(6): 701–737.
  19. Burnham TK, Neblett TR, Fine G. The application of the fluorescent antibody technic to the investigation of lupus erythematosus and various dermatoses. J Invest Dermatol. 1963; 41: 451–456.
  20. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979; 115(12): 1409–1415.
  21. Bowen JT. Twentieth Century Practice of Medicine. N Y William Wood Co. 1896; 5: 691–708.
  22. Pillat A. Über das Vorkommen von Chorioiditis bei Lupus erythematodes. Albrecht von Græfes Archiv für Ophthalmologie. 1935; 133(4): 566–577.
  23. Daly D. Central nervous system in acute disseminate lupus erythematosus. J Nerv Ment Dis. 1945; 102: 461–465.
  24. Piper PG. Disseminated lupus erythematosus with involvement of the spinal cord. J Am Med Assoc. 1953; 153(3): 215–217.
  25. Russell PW, Haserick JR, Zucker EM. Epilepsy in systemic lupus erythematosus; effect of cortisone and ACTH. AMA Arch Intern Med. 1951; 88(1): 78–92.
  26. Afeltra A, Garzia P, Mitterhofer AP, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42(4): 599–608, doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F.
  27. Reinhart A. Erfahrungen mit der Wassermann-Neisser-Bruckschen syphilis reaktion. Munch Med Wochenschr. 1909; 41: 1092–1097.
  28. Goeckerman WH. Lupus erythematosus as a systemic disease. JAMA: The Journal of the American Medical Association. 1923; 80(8): 542.
  29. Keefer E, Felty A. Acute disseminated lupus erythematosus. Bull Johns Hopkins Hosp. 1924; 35: 294–304.
  30. Lyon JM. Acute lupus erythematosus. Archives of Pediatrics & Adolescent Medicine. 1933; 45(3): 572.
  31. Rose E, Pillsbury DM. Acute disseminated lupus erythematosus — a systemic disease. Annals of Internal Medicine. 1939; 12(7): 951.
  32. Coburn A, Moore D. The plasma proteins in disseminate lupus erythematosus. Bull Johns Hopkins Hosp. 1943; 73: 196–221.
  33. Townes AS, Stewart CR, Osler AG. Immunologic studies of systemic lupus erythematosus. II. Variations of nucleoprotein-reactive gamma globulin and hemolytic serum complement levels with disease activity. Bull Johns Hopkins Hosp. 1963; 112: 202–219.
  34. Vaughan JH, Bayles TB, Favour CB. The response of serum gamma globulin level and complement titer to adrenocorticotropic hormone therapy in lupus erythematosus disseminatus. J Lab Clin Med. 1951; 37(5): 698–702.
  35. Hargraves M. Discovery of the LE cell and its morphology. Mayo Clin Proc. 1969; 9: 579–599.
  36. Miescher P, Fauconnet M. Absorption of L. E. factor by isolated cell nuclei. Experientia. 1954; 10: 252–253.
  37. Beck JS. Variations in the morphological patterns of "autoimmune" nuclear fluorescence. Lancet. 1961; 1(7188): 1203–1205.
  38. Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966; 45(11): 1732–1740.
  39. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with sera of patients with systemic lupus erythematosus. J Immunol Baltim Md 1950. 1966; 96: 464–471.
  40. Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020; 16(10): 565–579.
  41. Pangborn MC. A New Serologically Active Phospholipid from Beef Heart. Experimental Biology and Medicine. 1941; 48(2): 484–486.
  42. Conley CL, Hartman RCA. hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952; 31: 621–622.
  43. Lee SL, Sanders MA. disorder of blood coagulation in systemic lupus erythematosus. J Clin Invest. 1955; 34: 1814–1822.
  44. Bowie EJ, Thompson JH, Pascuzzi CA, et al. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963; 62: 416–430.
  45. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983; 2(8361): 1211–1214.
  46. Galli M, Barbui T, Comfurius P, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. The Lancet. 1990; 335(8705): 1544–1547.
  47. Matsuura E, Igarashi Y, Fujimoto M, et al. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990; 336(8708): 177–178.
  48. McNeil HP, Simpson RJ, Chesterman CN, et al. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990; 87(11): 4120–4124.
  49. Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol. 2014; 165(5): 609–617.
  50. Cohen A, Reynolds W, Franklin E, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis. 1971; 21: 643.
  51. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11): 1271–1277.
  52. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
  53. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8): 2677–2686.
  54. Aringer M, Costenbader K, Dörner T, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151–1159.
  55. Payne JA. postgraduate lecture on lupus erythematosus. Clin J. 1894; 4: 223–239.
  56. Bettley FR, Page F. Treatment of lupus erythematosus with mepacrine. Lancet. 1951; 2(6687): 755–758.
  57. Lewis HM, Frumess GM. Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report. AMA Arch Derm. 1956; 73(6): 576–581.
  58. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocortical hormone in arthritis: preliminary report. Ann Rheum Dis. 1949; 8(2): 97–104.
  59. Pollak VE, Pirani CL, Schwartz FD, et al. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med. 1964; 63(6): 537–550.
  60. Dubois EL. Nitrogen mustard in treatment of systemic lupus erythematosus. AMA Arch Intern Med. 1954; 93(5): 667–672.
  61. Austin H, Klippel J, Balow J, et al. Therapy of Lupus Nephritis. New England Journal of Medicine. 1986; 314(10): 614–619.
  62. Miescher PA, Riethmueller D. Diagnosis and treatment of systemic lupus erythematosus. Semin Hematol. 1965; 2: 1–28.
  63. Cruchaud A, Pometta D, Rousso C, et al. Treatment of systemic lupus erythematosus with antimetabolites. Relations between the clinical course and immunological reactions. Helv Med Acta. 1967; 34(1): Suppl:141–Suppl:142.
  64. Petschner F, Walker UA, Schmitt-Gräff A, et al. Catastrophic systemic lupus erythematosus" with Rosai-Dorfman sinus histiocytosis. Successful treatment with anti-CD20/rutuximab. Dtsch Med Wochenschr. 2001; 126(37): 998–1001.
  65. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000; 343(16): 1156–1162.
  66. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis. 2011; 57(2): 235–244.
  67. Navarra SV, Guzmán RM, Gallacher AE, et al. BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767): 721–731.
  68. String of successful trials in SLE: have we cracked the code? Lupus Science & Medicine [Internet]. https://lupus.bmj.com/content/7/1/e000380 (26.11.2020).

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl